DOCSLIB.ORG

Vaccinia Viruses As Vectors for Vaccine Antigens Vaccinia Viruses As Vectors for Vaccine Antigens

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccinia Viruses As Vectors for Vaccine Antigens Vaccinia Viruses As Vectors for Vaccine Antigens Vaccinia Viruses as Vectors for Vaccine Antigens Vaccinia Viruses as Vectors for Vaccine Antigens Proceedings of the Workshop on Vaccinia Viruses as Vectors for Vaccine Antigens, held November 13-14, 1984, in Chevy Chase, Maryland, U. S.A. Editor: GeraldV.Quinnan,Jr.,M.D. Director, Division of Virology Center for Drugs and Biologics Food and Drug Administration Bethesda, Maryland Elsevier New York • Amsterdam. Oxford .... i © 1985 by Elsevier Science Publishing Co., Inc. All rights reserved. This book has been registered with the Copyright Clearance Center, Inc. For further information, please contact the Copyright Clearance Center, Salem, Massachusetts. Published by: Elsevier Science Publishing Co., Inc. 52 Vanderbilt Avenue, New York, New York 10017 Sole distributors outside the United States and Canada: Elsevier Science Publishers B.V. P.O. Box 211, 1000 AE Amsterdam, the Netherlands Library of Congress Cataloging in Publication Data Workshop in Vaccinia Viruses as Vectors for Vaccine Antigens (1984: Chevy Chase, Md.) Vaccinia viruses as vectors for vaccine antigens. Includes index. I. Vaccines--Congresses. 2. Vaccinia--Congresses. 3. Viralantigens-- Congresses. 4. Smallpox--Congresses. I. Quinnan, Gerald V. 1I. Title. [DNLM: 1. Antigens, Viral--immunology--Congresses. 2. VacciniaVirus-- genetics--congresses. 3. VacciniaVirus--immunology--congresses. 4. Viral Vaccines--immunology--congresses. QW 165.5.P6 W926v 1984] QR189.W674 1984 615'.372 85-12960 ISBN 0-444-00984-1 Manufactured in the United States of America CONTENTS Preface ..... ..... ° . ............... ix Participants .............................. xi Part I: BIOLOGY OF VACCINIA AND OTHER ORTHOPOX VIRUSES I Chairpersons: G. Schild and J. Nakano Vaccinia Virus ...................... 3 D. Baxby Aspects of the Biology of Orthopox Viruses Relevant to the Use of Recombinant Vaccines as Field Vaccines ...... 9 K.R. Dumbell Molecular Biology of Vaccinia Virus: Structure of Pox Virus DNA ................ 15 W.K. Joklik Molecular Biology of Vaccinia Virus: Strategies for Cloning and Expression of Foreign Genes ......... 27 B. Moss Genetic Basis for Vaccinia Virus Virulence ........ 37 R.M.L. Bullet and B. Moss Part II: SMALLPOX VACCINES 47 Chairperson: G.V. Quinnan, Jr. Complications of Smallpox Vaccination .......... 49 I. Arita and F. Fenner _ Utilization of Vaccine in the Global Eradication of Smallpox ......................... 61 D.A. H_nderson and I. Arita \ _ Vaccinia Virus Vaccines: Virulence and Attenuation of Vaccinia Strain Variation ................ 69 _i J.M. Neff A Comparative Study of Four Smallpox Vaccines in Children ......................... 77 K. McIntosh Low Neurovirulent Variant of Lister Strain of Vaccinia Virus ...................... 85 S. Kato Properties of Attenuated Mutant of Vaccinia Virus, LC16m8, Derived from Lister Strain ............ 87 S. Hashlzume, R. Yoshizawa, M. Morita and K. Suzuki Immunogenicity of Vaccinia Viruses: Responses to Vaccination ................. 101 J.D. Millar Smallpox Vaccine In Vivo Production and Testlng ..... 109 D.P. Metzgar vl Tissue Culture Smallpox Vaccine ............ 113 A.C. Hekker Capability of Developing Countries to Produce Vaccinia Vector Vaccine ..................... 117 I. Arita Part III: EXPERIMENTAL RECOMBINANT VACCINIA VIRUS VACCINES 127 Chairpersons: R. Chanock and W. Dowdle Vaccinia Virus Recombinants as Live Vaccines Against Hepatitis B Virus and Malaria ............. 129 G.L. Smith and B. Moss Vaccinia Vectored Vaccines ............... 137 E. Paoletti, M.E. Perkus, A. Piccini, S. Wos, and B.R. Lipinskas Infectious Vaccinia Virus Recombinants Express Herpes Simplex Virus Glycoprotein D and Protect Against Lethal and Latent Infections of HSV .......... 153 K. Cremer, C. wohlenberg, M. Mackett, B. Mos% and A.L. Notkins Induction of Virus Neutralizing Antibodies and Protection Against Rabies Using a Vaccinia Rabies Glycoprotein Recombinant ................ 163 B. Dietzschold, T.J. Wiktor, and H. Koprowski Influenza Virus Specific Cell-Mediated Immunity to Vaccinia Virus Recombinants .............. 169 J.R. Bennink, J.W. Yewdell, G.L. Smith, and B. Moss Intranasal Vaccination with Recombinant Vaccinia Containing Influenza Hemagglutinin Prevents Both Influenza Virus Pneumonia and Nasal Infection: Intradermal Vaccination Prevents only Viral Pneumonia ....................... 175 P.A. Small, Jr., G.L. Smith, and B. Moss Infectious Vaccinia Virus Recombinants that Express the Epstein-Barr Virus Membrane Antigen gp340 ..... 179 M. Mackett and J.R. Arrand Vaccinia Virus Recombinants Expressing Vesicular Stomatitis Genes Immunize Mice and Cattle ....... 187 T. Yilma, M. Mackett, J.K. Rose, and B. Moss Infectious Vaccinia Virus Recombinant that Expresses the Surface Antigen of Porcine Transmissible Gastroenteritis Virus (TGEV) .............. 201 S. Hu, J. Bruszewski, and R. Smalling Part IV: OTHER VIRUSES AS VECTORS FOR VACCINE ANTIGENS 209 Chairpersons: R. Chanock and W. Dowdle Genetic Engineering of Herpes Simplex Virus Genomes for Attenuation and Expression of Foreign Genes .... 211 B. Roizman and M. Arsenakis vii Part V: CONSIDERATIONS OF THE SAFETY, EFFICACY AND POTENTIAL APPLICATIONS OF RECOMBINANT VACCINIA VIRUSES 225 Chairperson: G. Noble Potential Applications of Vacclnla Virus Vectors for Immunoprophylaxls ................... 227 F. Brown Considerations of Safety, Efficacy and Potential Applications of Vacclnla Vectors for Immunoprophylaxls: An Alternative Approach for Control of Human Diseases For Which Vaccines are Available ........... 231 D.T. Karzon Considerations of Safety, Efficacy, and Potential Application of Vacclnla Vectored Vaccines for Immunoprophylaxls Against Animal Diseases ....... 237 F.A. Murphy Panel Discussion: Needs for Further Laboratory and Clinical Research, Safety and Ethical Considerations. 241 F. Dienhardt, K. Warren, W. Jordan, and G.V. Qulnnan, Jr. Index ......................... 253 ix PREFACE The use of viruses as vectors for expression of heterologous antigens in mammalian cells in vivo exemplifies an exciting recent advance in the application of recombinant DNA technology for vaccine production. In many respects vaccinia virus is highly suited for this purpose. Vaccinia virus vaccines were used extensively world-wide during the smallpox eradication campaign, and were generally very well tolerated, highly i mmunogenic, easily manufactured and readily applied in mass vaccination efforts. Even with its outstanding performance record, however, the possibility of reintroduc- ing the use of this virus on a wide scale in man or animals raises many public health and ethical concerns. Although very rarely, serious or fatal complications of vaccinia virus infections did occur, and they occurred in contacts of vaccinees as well as in vaccinees themselves. The potential occurrence and significance of similar complications must be evaluated in considering approaches to devel¢_ment of recombinant vaccinia virus vaccines. Even if there were no known risks, the reintroduction of the virus into populations that are not: exposed currently should be done only after careful consideration of the benefits to be achieved. Other major questions that must be addressed at: the outset include: What strain(s) of vaccinia virus should be used? How should vaccines be manufactured? What tests should be done to assure acceptability of vaccines for use in field trials? What biologic propezties of vaccine strains should be evaluated? In whom should vaccine trials be performed? This book represents the proceedings of a Workshop on Vaccinia Viruses as Vectors for Vaccine Antigens, cosponsored by the United States Public Health Service, the World Health Organization, and the National Institute for Biologic Standards and Control, London, held November 13 and 14, 1984, in Chevy Chase, Maryland. The purpose of the Workshop was to begin devel- oping answers to the questions indicated above. The data presented and relevant to these questions emanate both from studies performed during the smallpox eradication campaign and from exciting recent laboratory work on molecular biology, expression of foreign genes, determinants of virulence, and immunology of vaccinia virus infections. It is evident from these data that there are unlikely to be any insurmountable objections to the use of recombinant vaccinia virus vaccines, and that they offer great promise for use as safe and effective immunogens. Work on developing can- didate strains for human administration will hopefully progress rapidly. The use of vectors other than vaccinia virus may also prove feasible. This Workshop was followed by a meeting of consultants to the World Health Organization with the purpose of advising on evidence relevant to the public health, ethical and scientific concerns about these recombinant vaccines, and formulating draft requirements for the use of recombinant vaccinia virus vaccines. These draft requirements will be under continued development for many months. However, the intent of the World Health Organization to publish them should be viewed as an indication of the enthusiasm with which this approach has been greeted. The list cf human and veterinary diseases against which vaccines of this type might be used is long and the death and suffering that might be prevented are great. The process of developing any vaccine is an arduous one, and it is never certain at the outset that any specific approach will result in a safe and effective product. It is clear that the long history of vaccinia virus is far from over and there are many
Load more

Recommended publications
  • Vaccinia Belongs to a Family of Viruses That Is Closely Related to the Smallpox Virus
    VACCINIA INFECTION What is it? Vaccinia belongs to a family of viruses that is closely related to the smallpox virus. Because of the similarities between the smallpox and vaccinia viruses, the vaccinia virus is used in the smallpox vaccine. When this virus is used as a vaccine, it allows our immune systems to develop immunity against smallpox. The smallpox vaccine does not actually contain smallpox virus and cannot cause smallpox. Vaccination usually prevents smallpox infection for at least ten years. The vaccinia vaccine against smallpox was used to successfully eradicate smallpox from the human population. More recently, this virus has also become of interest due to concerns about smallpox being used as an agent of bioterrorism. How is the virus spread? Vaccinia can be spread by touching the vaccination site before it has fully healed or by touching clothing or bandages that have been contaminated with the live virus during vaccination. In this manner, vaccinia can spread to other parts of the body and to other individuals. It cannot be spread through the air. What are the symptoms of vaccinia? Vaccinia virus symptoms are similar to smallpox, but milder. Vaccinia may cause rash, fever, headache and body aches. In certain individuals, such as those with weak immune systems, the symptoms can be more severe. What are the potential side effects of the vaccinia vaccine for smallpox? Normal reactions are mild and go away without any treatment.These include: Soreness and redness in the arm where the vaccine was given Slightly swollen, sore glands in the armpits Low grade fever One in approximately three people will feel badly enough to miss school, work or recreational activities Trouble sleeping Serious reactions are not very common but can occur in about 1,000 in every 1 million people who are vaccinated for the first time.
    [Show full text]
  • Vaccinia Virus
    APPENDIX 2 Vaccinia Virus • Accidental infection following transfer from the vac- cination site to another site (autoinoculation) or to Disease Agent: another person following intimate contact Likelihood of Secondary Transmission: • Vaccinia virus • Significant following direct contact Disease Agent Characteristics: At-Risk Populations: • Family: Poxviridae; Subfamily: Chordopoxvirinae; • Individuals receiving smallpox (vaccinia) vaccination Genus: Orthopoxvirus • Individuals who come in direct contact with vacci- • Virion morphology and size: Enveloped, biconcave nated persons core with two lateral bodies, brick-shaped to pleo- • Those at risk for more severe complications of infec- morphic virions, ~360 ¥ 270 ¥ 250 nm in size tion include the following: • Nucleic acid: Nonsegmented, linear, covalently ᭺ Immune-compromised persons including preg- closed, double-stranded DNA, 18.9-20.0 kb in length nant women • Physicochemical properties: Virus is inactivated at ᭺ Patients with atopy, especially those with eczema 60°C for 8 minutes, but antigen can withstand 100°C; ᭺ Patients with extensive exfoliative skin disease lyophilized virus maintains potency for 18 months at 4-6°C; virus may be stable when dried onto inanimate Vector and Reservoir Involved: surfaces; susceptible to 1% sodium hypochlorite, • No natural host 2% glutaraldehyde, and formaldehyde; disinfection of hands and environmental contamination with soap Blood Phase: and water are effective • Vaccinia DNA was detected by PCR in the blood in 6.5% of 77 military members from 1 to 3 weeks after Disease Name: smallpox (vaccinia) vaccination that resulted in a major skin reaction. • Progressive vaccinia (vaccinia necrosum or vaccinia • In the absence of complications after immunization, gangrenosum) recently published PCR and culture data suggest that • Generalized vaccinia viremia with current vaccines must be rare 3 weeks • Eczema vaccinatum after vaccination.
    [Show full text]
  • Evaluation of Recombinant Vaccinia Virus—Measles Vaccines in Infant Rhesus Macaques with Preexisting Measles Antibody
    Virology 276, 202–213 (2000) doi:10.1006/viro.2000.0564, available online at http://www.idealibrary.com on Evaluation of Recombinant Vaccinia Virus—Measles Vaccines in Infant Rhesus Macaques with Preexisting Measles Antibody Yong-de Zhu,*,1 Paul Rota,† Linda Wyatt,‡ Azaibi Tamin,† Shmuel Rozenblatt,‡,2 Nicholas Lerche,* Bernard Moss,‡ William Bellini,† and Michael McChesney*,§,3 *The California Regional Primate Research Center and §Department of Pathology, School of Medicine, University of California, Davis, California 95616; †Measles Virus Section, Respiratory and Enteric Viruses Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333; and ‡Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 Received June 20, 2000; returned to author for revision July 28, 2000; accepted August 1, 2000 Immunization of newborn infants with standard measles vaccines is not effective because of the presence of maternal antibody. In this study, newborn rhesus macaques were immunized with recombinant vaccinia viruses expressing measles virus hemagglutinin (H) and fusion (F) proteins, using the replication-competent WR strain of vaccinia virus or the replication- defective MVA strain. The infants were boosted at 2 months and then challenged intranasally with measles virus at 5 months of age. Some of the newborn monkeys received measles immune globulin (MIG) prior to the first immunization, and these infants were compared to additional infants that had maternal measles-neutralizing antibody. In the absence of measles antibody, vaccination with either vector induced neutralizing antibody, cytotoxic T cell (CTL) responses to measles virus and protection from systemic measles infection and skin rash.
    [Show full text]
  • Human Papillomavirus and HPV Vaccines: a Review
    Human papillomavirus and HPV vaccines: a review FT Cutts,a S Franceschi,b S Goldie,c X Castellsague,d S de Sanjose,d G Garnett,e WJ Edmunds,f P Claeys,g KL Goldenthal,h DM Harper i & L Markowitz j Abstract Cervical cancer, the most common cancer affecting women in developing countries, is caused by persistent infection with “high-risk” genotypes of human papillomaviruses (HPV). The most common oncogenic HPV genotypes are 16 and 18, causing approximately 70% of all cervical cancers. Types 6 and 11 do not contribute to the incidence of high-grade dysplasias (precancerous lesions) or cervical cancer, but do cause laryngeal papillomas and most genital warts. HPV is highly transmissible, with peak incidence soon after the onset of sexual activity. A quadrivalent (types 6, 11, 16 and 18) HPV vaccine has recently been licensed in several countries following the determination that it has an acceptable benefit/risk profile. In large phase III trials, the vaccine prevented 100% of moderate and severe precancerous cervical lesions associated with types 16 or 18 among women with no previous infection with these types. A bivalent (types 16 and 18) vaccine has also undergone extensive evaluation and been licensed in at least one country. Both vaccines are prepared from non-infectious, DNA-free virus-like particles produced by recombinant technology and combined with an adjuvant. With three doses administered, they induce high levels of serum antibodies in virtually all vaccinated individuals. In women who have no evidence of past or current infection with the HPV genotypes in the vaccine, both vaccines show > 90% protection against persistent HPV infection for up to 5 years after vaccination, which is the longest reported follow-up so far.
    [Show full text]
  • Here, There, and Everywhere: the Wide Host Range and Geographic Distribution of Zoonotic Orthopoxviruses
    viruses Review Here, There, and Everywhere: The Wide Host Range and Geographic Distribution of Zoonotic Orthopoxviruses Natalia Ingrid Oliveira Silva, Jaqueline Silva de Oliveira, Erna Geessien Kroon , Giliane de Souza Trindade and Betânia Paiva Drumond * Laboratório de Vírus, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais: Belo Horizonte, Minas Gerais 31270-901, Brazil; [email protected] (N.I.O.S.); [email protected] (J.S.d.O.); [email protected] (E.G.K.); [email protected] (G.d.S.T.) * Correspondence: [email protected] Abstract: The global emergence of zoonotic viruses, including poxviruses, poses one of the greatest threats to human and animal health. Forty years after the eradication of smallpox, emerging zoonotic orthopoxviruses, such as monkeypox, cowpox, and vaccinia viruses continue to infect humans as well as wild and domestic animals. Currently, the geographical distribution of poxviruses in a broad range of hosts worldwide raises concerns regarding the possibility of outbreaks or viral dissemination to new geographical regions. Here, we review the global host ranges and current epidemiological understanding of zoonotic orthopoxviruses while focusing on orthopoxviruses with epidemic potential, including monkeypox, cowpox, and vaccinia viruses. Keywords: Orthopoxvirus; Poxviridae; zoonosis; Monkeypox virus; Cowpox virus; Vaccinia virus; host range; wild and domestic animals; emergent viruses; outbreak Citation: Silva, N.I.O.; de Oliveira, J.S.; Kroon, E.G.; Trindade, G.d.S.; Drumond, B.P. Here, There, and Everywhere: The Wide Host Range 1. Poxvirus and Emerging Diseases and Geographic Distribution of Zoonotic diseases, defined as diseases or infections that are naturally transmissible Zoonotic Orthopoxviruses. Viruses from vertebrate animals to humans, represent a significant threat to global health [1].
    [Show full text]
  • Vaccinia Virus and Viral Vectors
    Vaccinia Virus and Viral Vectors Background Vaccinia virus is a member of the family Poxviridae, which are enveloped viruses with double stranded DNA genomes. These viruses replicate in the cytoplasm of mammalian cells because they do not require host replication machinery found in the nucleus. This trait allows poxviruses to replicate in enucleated cells. Vaccinia virus has a large genome, which allows for large inserts (up to 25 kb of foreign DNA) and a high level of DNA expression from prokaryotes or eukaryotes due to being regulated by a strong poxviral promoter. The foreign genes are stably inserted into the viral genome, allowing for efficient replication and expression including proper post translational modification in the infected cell. While transduction with the viral vector will be transient, there will be high levels of expression of the transgene. Vaccinia virus is a human pathogen, and while it is the strain of poxvirus used for the small pox vaccine, it can cause flu-like symptoms in healthy individuals and more serious complications in immunocompromised individuals. Vaccinia virus is transmittable to others if contact with the vaccination site or area of infection occurs. Recombinant vaccines that utilize highly attenuated strains such as Modified Vaccinia virus Ankara (MVA) and NYVAC have been created to treat diseases. These attenuated strains are replication deficient and are recommended for use as vectors to replace wild type vaccinia virus. The primary safety concern with vaccinia viral vectors is the transgene. Examples of high risk transgenes are those that encode a toxin or are immunomodulatory. Also, when replication deficient strains are used in the presence of other orthopox viruses, there is a possibility of recombination to create replication competent viral vectors with the genes of interest.
    [Show full text]
  • Substantial Equivalence Determination Decision Summary
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: K181205 B. Purpose for Submission: Modification of device C. Measurand: Non-variola Orthopoxvirus DNA target sequence D. Type of Test: In vitro molecular diagnostic test E. Applicant: Centers for Disease Control and Prevention F. Proprietary and Established Names: Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set G. Regulatory Information: 1. Regulation section: 21 CFR 866.3315: Nucleic acid based reagents for detection of non-variola orthopoxviruses 2. Classification: Class II (Special Controls) 3. Product code: PBK 4. Panel: Microbiology (83) 1 H. Intended Use: 1. Intended use(s): The Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set is intended for the in vitro qualitative presumptive detection of non-variola Orthopoxvirus DNA extracted from human pustular or vesicular rash specimens and viral cell culture lysates submitted to a Laboratory Response Network (LRN) reference laboratory. The assay detects non- variola Orthopoxvirus DNA, including Vaccinia, Cowpox, Monkeypox and Ectromelia viruses at varying concentrations. This assay does not differentiate Vaccinia virus or Monkeypox virus from other Orthopoxviruses detected by this assay and does not detect Variola virus. Refer to the CDC algorithm, Acute, Generalized Vesicular or Pustular Rash Illness Testing Protocol in the United States for recommended testing and evaluation algorithms for patients presenting with acute, generalized pustular or vesicular rash illness. Results of this assay are for the presumptive identification of non-variola Orthopoxvirus DNA. These results must be used in conjunction with other diagnostic assays and clinical observations to diagnose Orthopoxvirus infection. The assay should only be used to test specimens with low/moderate risk of smallpox.
    [Show full text]
  • Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice
    pathogens Article Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice Sergei N. Shchelkunov *, Stanislav N. Yakubitskiy, Kseniya A. Titova, Stepan A. Pyankov and Alexander A. Sergeev State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk 630559, Russia; [email protected] (S.N.Y.); [email protected] (K.A.T.); [email protected] (S.A.P.); [email protected] (A.A.S.) * Correspondence: [email protected] Abstract: Following the WHO announcement of smallpox eradication, discontinuation of smallpox vaccination with vaccinia virus (VACV) was recommended. However, interest in VACV was soon renewed due to the opportunity of genetic engineering of the viral genome by directed insertion of foreign genes or introduction of mutations or deletions into selected viral genes. This genomic technology enabled production of stable attenuated VACV strains producing antigens of various infectious agents. Due to an increasing threat of human orthopoxvirus re-emergence, the development of safe highly immunogenic live orthopoxvirus vaccines using genetic engineering methods has been the challenge in recent years. In this study, we investigated an attenuated VACV LIVP-GFP (TK-) strain having an insertion of the green fluorescent protein gene into the viral thymidine kinase gene, which was generated on the basis of the LIVP (Lister-Institute for Viral Preparations) strain used in Citation: Shchelkunov, S.N.; Russia as the first generation smallpox vaccine. We studied the effect of A34R gene modification Yakubitskiy, S.N.; Titova, K.A.; and A35R gene deletion on the immunogenic and protective properties of the LIVP-GFP strain.
    [Show full text]
  • Two Major Antigenic Polypeptides of Molluscum Contagiosum Virus
    284 Two Major Antigenic Polypeptides of Molluscum Contagiosum Virus Takahiro Watanabe, Shigeru Morikawa, Kenji Suzuki, Departments of Virology II, Virology I, and Pathology, National Tatsuo Miyamura, Kunihiko Tamaki, and Yoshiaki Ueda Institute of Infectious Diseases, and Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan A library of molluscum contagiosum virus (MCV) transferred into the cowpox vector expression system was screened with 12 sera from molluscum patients. Two recombinant proteins of 70 and 34 kDa were detected by immunoblotting and mapped to the open-reading frames MC133L and MC084L, respectively. Consensus sites were found between the C-terminus of the 70-kDa MCV protein and the 14-kDa fusion protein of vaccinia and variola virus, and between the 34-kDa MCV protein and the 37.5-kDa viral membrane±associated protein of vaccinia and variola virus. Rabbit Downloaded from https://academic.oup.com/jid/article/177/2/284/925332 by guest on 30 September 2021 antisera against these two proteins were prepared. An immuno¯uorescence study demonstrated that the 70- and 34-kDa proteins were predominantly expressed on the surface of recombinant virus± infected HeLa cells, indicating the potential to be inserted into the membrane. On immunoelectron microscopy, antiserum against 70-kDa protein showed signi®cant labeling of the MCV membrane, while the antiserum against 34-kDa protein failed to do so. After the eradication of variola virus in 1977, molluscum conditions indicated that they were essentially collinear and contagiosum virus (MCV) has been the sole member of the that minor sequence heterogeneity among subtypes contributed poxviruses speci®c for humans.
    [Show full text]
  • Rational Design of Live-Attenuated Vaccines Against Herpes Simplex Viruses
    viruses Review Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses Brent A. Stanfield 1, Konstantin G. Kousoulas 2,3,*, Agustin Fernandez 3 and Edward Gershburg 3,* 1 Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; [email protected] 2 Division of Biotechnology and Molecular Medicine, Louisiana State University, Baton Rouge, LA 70803, USA 3 Rational Vaccines Inc., Woburn, MA 01801, USA; [email protected] * Correspondence: [email protected] (K.G.K.); [email protected] (E.G.) Abstract: Diseases caused by human herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) affect millions of people worldwide and range from fatal encephalitis in neonates and herpes keratitis to orofacial and genital herpes, among other manifestations. The viruses can be shed efficiently by asymptomatic carriers, causing increased rates of infection. Viral transmission occurs through direct contact of mucosal surfaces followed by initial replication of the incoming virus in skin tissues. Subsequently, the viruses infect sensory neurons in the trigeminal and lumbosacral dorsal root ganglia, where they are primarily maintained in a transcriptionally repressed state termed “latency”, which persists for the lifetime of the host. HSV DNA has also been detected in other sympathetic ganglia. Periodically, latent viruses can reactivate, causing ulcerative and often painful lesions primarily at the site of primary infection and proximal sites. In the United States, recurrent genital herpes alone accounts for more than a billion dollars in direct medical costs per year, while there are much higher costs associated with the socio-economic aspects of diseased patients, such as loss of productivity due to mental anguish.
    [Show full text]
  • Medication Guide Smallpox Vaccine, Live ACAM2000
    Medication Guide Smallpox (Vaccinia) Vaccine, Live ACAM2000® Please read this Medication Guide before you receive a vaccination with ACAM2000. This Guide does not take the place of talking to your healthcare provider about ACAM2000 and the smallpox disease. What is the most important information I should know about the ACAM2000 smallpox vaccine? • If you are at a high risk for being exposed to smallpox, you should be vaccinated even if you have health problems, unless you have certain problems with your immune system. People who have health problems may have a higher chance of getting serious side effects from vaccination but are also those who have a higher chance of dying from the smallpox disease. • ACAM2000 may cause serious heart problems called myocarditis and pericarditis, or swelling of the heart tissues. In studies, about 1 in every 175 persons who got the vaccine for the first time may have experienced myocarditis and/or pericarditis. On rare occasions these conditions can result in an irregular heart beat and death. Your chances of getting heart problems from the vaccine are lower if you have already had this vaccine before. You can have myocarditis and/or pericarditis even if you have no symptoms. Call your healthcare provider or get emergency help right away if you have: o chest pain or pressure o fast or irregular heartbeat o breathing problems See “What are the possible side effects of ACAM2000?” • Because the vaccine has a live virus, it can spread to other parts of your body or to other people if you touch the vaccination site and then touch other parts of your body or other people.
    [Show full text]
  • Broad Target Cell Selectivity of Kaposi's Sarcoma-Associated Herpesvirus Glycoprotein-Mediated Cell Fusion and Virion Entry ⁎ Johnan A.R
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Virology 354 (2006) 7–14 www.elsevier.com/locate/yviro Broad target cell selectivity of Kaposi's sarcoma-associated herpesvirus glycoprotein-mediated cell fusion and virion entry ⁎ Johnan A.R. Kaleeba, Edward A. Berger Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 4, Room 237, Bethesda, MD 20892, USA Received 23 November 2005; returned to author for revision 21 April 2006; accepted 15 June 2006 Available online 2 August 2006 Abstract The molecular mechanism of Kaposi's sarcoma-associated herpesvirus (KSHV, human herpesvirus 8) entry is poorly understood. We tested a broad variety of cell types of diverse species and tissue origin for their ability to function as targets in a quantitative reporter gene assay for KSHV- glycoprotein-mediated cell fusion. Several human, non-human primate, and rabbit cell lines were efficient targets, whereas rodent and all human lymphoblastoid cell lines were weak targets. Parallel findings were obtained with a virion entry assay using a recombinant KSHV encoding a reporter gene. No correlation was observed between target cell activity and surface expression of α3β1 integrin, a proposed KSHV receptor. We hypothesize that target cell permissiveness in both the cell fusion and virion entry assays reflects the presence of a putative KSHV fusion–entry receptor. Published by Elsevier Inc. Keywords: Human herpesvirus 8; Host range; Virus glycoprotein; Cell fusion assay; Virus entry assay; Vaccinia virus expression system; β-galactosidase; Enhanced green fluorescent protein; Virus receptor; Integrin Introduction more cellular entry receptors (Spear and Longnecker, 2003).
    [Show full text]